For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research And Development | 7,140 | |||
| General And Administrative | 4,492 | |||
| Total operating expenses | 11,632 | |||
| Operating loss | -11,632 | |||
| Financial expenses | 277 | |||
| Loss before income taxes | -11,909 | |||
| Income tax | 3 | |||
| Net loss for the year | -11,912 | |||
| Basic EPS | 8.96 | |||
| Diluted EPS | 8.96 | |||
| Basic Average Shares | 1,329,515 | |||
| Diluted Average Shares | 1,329,515 | |||
Silexion Therapeutics Corp (SLXNW)
Silexion Therapeutics Corp (SLXNW)